Horizon Pharma Public Limited Company (HZNP)
(Delayed Data from NSDQ)
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
M&A, Innovation & New Drugs to Drive Pharma Stocks
by Zacks Equity Research
The new tax law, which cuts the corporate tax rate from 35% to 21% and encourages companies to bring back cash held overseas at a one-time tax rate of 10%, is expected to spur merger activity.
5 Low Price-to-Book Stocks With Great Growth Prospects
by Zacks Equity Research
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
Horizon Pharma (HZNP) Tops Q4 Earnings, Provides 2018 View
by Zacks Equity Research
Horizon Pharma (HZNP) Q4 results are driven by growth from the orphan unit and the rheumatology business.
Horizon Pharma (HZNP) Tops Q4 Earnings, Revenues Beat
by Zacks Equity Research
Horizon Pharma (HZNP) topped earnings and sales in the fourth quarter.
Is a Beat in Store for Horizon Pharma (HZNP) in Q4 Earnings?
by Zacks Equity Research
On Horizon Pharma's (HZNP) fourth-quarter 2017 earnings call, investors focus will be on the performance of its business units and key products.
Horizon Pharma Gets FDA Nod for Procysbi Label Expansion
by Zacks Equity Research
The FDA approves label expansion for Horizon Pharma's (HZNP) Procysbi (cysteamine bitartrate) delayed-release capsules for children aged a year and older with nephropathic cystinosis.
Horizon Pharma (HZNP) Tops Q3 Earnings & Sales, Ups View
by Zacks Equity Research
Horizon Pharma (HZNP) Q3 results were driven by growth from the orphan and rheumatology business.
Horizon (HZNP) Tops Q3 Earnings, Shares Up
by Ekta Bagri
Horizon Pharma (HZNP) topped earnings and sales in the third quarter. Consequently, share are trading up in pre-market trading.
Key Predictions for Q3 Earnings Reports of MYL, HZNP & KERX
by Zacks Equity Research
The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if generic maker Mylan and other small companies follow suit.
Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised)
by Zacks Equity Research
Horizon Pharma???s shares have declined 12% in the year so far, underperforming the industry???s gain of 0.9%.
Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store?
by Zacks Equity Research
Horzion Pharma's (HZNP) primary care business is under pressure and we expect earnings to disappoint in the third quarter.
Is Horizon Pharma (HZNP) A Suitable Pick for Value Investors?
by Zacks Equity Research
Let's find out if Horizon Pharma Public Limited Company (HZNP) stock is a good choice for value-oriented investors right now
Horizon Pharma (HZNP) Soars: Stock Adds 10.5% in Session
by Zacks Equity Research
Horizon Pharma Public Limited Company (HZNP) was a big mover last session, as the company saw its shares rise nearly 11% on the day amid huge volumes.
Horizon Pharma (HZNP) Q2 Earnings & Sales Top, Raises View
by Zacks Equity Research
Horizon Pharma plc (HZNP) topped both earnings and sales estimate in second-quarter 2017 and raised its sales guidance for 2017.
Horizon Pharma (HZNP) Tops Earnings in Q2, Shares Up
by Ekta Bagri
Horizon Pharma (HZNP) topped earnings and sales estimates in the second quarter of 2017 and upped its annual sales guidance.
Can Horizon Pharma (HZNP) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
Horizon Pharma (HZNP) is set to report second-quarter results next week and we expect investor focus on sales of key drugs.
Horizon Pharma Gets Health Canada Approval for Procysbi
by Zacks Equity Research
Horizon Pharma plc (HZNP), announced that it has received approval in Canada for Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children of 2 years old and more.
Horizon Pharma (HZNP) Up 11.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Horizon Pharma (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Falling Earnings Estimates Signal Weakness Ahead for Horizon Pharma (HZNP)
by Zacks Equity Research
One stock that you may want to consider dropping is Horizon Pharma Public Limited Company (HZNP), which has witnessed a significant price decline in the past four weeks
Horizon (HZNP) Sells European Rights for Procysbi & Quinsair
by Zacks Equity Research
Horizon Pharma plc (HZNP) signed an agreement with Chiesi Farmaceutici S.p.A. to sell European rights for Procysbi and Quinsair.
Horizon (HZNP) Falls on Q1 Earnings Miss, Guidance Trimmed
by Zacks Equity Research
Horizon Pharma plc (HZNP) reported first-quarter 2017 earnings of 21 cents per share, down from 25 cents in the year-ago quarter. Reported earnings also missed the Zacks Consensus Estimate of 25 cents.
Here's Why Shares of Horizon Pharma (HZNP) are Cratering Today
by Madeleine Johnson
On Monday, shares of biopharmaceutical company Horizon Pharma (HZNP) are cratering, down over 34% to $10.09 per share in afternoon trading after they reported first-quarter financial results that missed expectations.
Horizon Pharma (HZNP) Misses Q1 Earnings, Shares Crash
by Madhu Goel
Horizon Pharma???s first-quarter 2017 earnings missed expectations.
Mylan (MYL) Q1 Earnings: Will the Stock Pull a Surprise?
by Zacks Equity Research
Mylan N.V. (MYL) is scheduled to report first-quarter 2017 results on May 10, before the market opens.
Should You Buy Horizon Pharma PLC (HZNP) Ahead of Earnings?
by Zacks Equity Research
Horizon Pharma PLC (HZNP) seems to be a great stock Ahead of Earnings on the back of its solid zacks rank and positive earnings ESP.